Okinawa Medix K.K.

Okinawa Medix K.K., a Japanese for-profit corporation headquartered in Haebaru, Okinawa and a subsidiary of Seiko Co., Ltd., supplies Class VIII medical equipment, laboratory reagents, diagnostic cartridges, and maintenance services to the U.S. Department of Defense as a prime contractor, operating exclusively in the full-and-open market with no set-aside designation across its federal footprint. The vendor holds no SBA certifications and competes as a large business.

Okinawa Medix serves as the sole-source logistics partner for U.S. military medical operations in the Pacific region, with near-total customer concentration in the Defense Logistics Agency Troop Support Pacific (180 awards, $25.7 million combined potential value, 63% of footprint by award count) and the Department of the Navy Bureau of Medicine and Surgery (172 awards, $7.3 million, 45% of footprint), both anchored on operations supporting the U.S. Naval Hospital Okinawa and the 18th Medical Group at Kadena Air Base. The Defense Logistics Agency Energy ranks third (13 awards, $5.3 million), driven by two large laboratory-equipment purchase orders placed in January 2024 valued at $2 million and $3.1 million, respectively, for Analytik Jena MultiEA sulfur analyzers. Concentration by dollar value mirrors concentration by award count — the top two agencies represent 98% of combined potential value across six customer entities. The Defense Health Agency places smaller but recurring preventive-maintenance and equipment-service purchase orders (11 awards, $497 thousand).

Capability delivery centers on medical consumables, particularly I-SAT cartridges (point-of-care laboratory diagnostic supplies), SYSMEX hematology reagents, microbiological media plates, and related laboratory analyzers, ordered through multiple single-award Indefinite Delivery Contracts with DLA Troop Support Pacific. Four active IDCs carry ceiling values ranging from $99,278.58 to $574,204.95, with completion dates extending through November 2027. The largest vehicle, SPE8EQ22D0001 ($574,204.95 ceiling, awarded November 2021, expiring November 2024), has generated 50 delivery orders valued at $4.7 million. A November 2024 IDC award (SPE8EQ25D0002, $455,640.17 ceiling) and a November 2024 award (SPE8EQ25D0001, $99,278.58 ceiling) anchor near-term task-order activity. Representative delivery orders include a $3.3 million order for SYSMEX reagents and media plates (September 2022), a $281,000 order for I-SAT cartridges (June 2022), and a $57,437.47 purchase order from the Defense Health Agency for laboratory analyzer preventive maintenance (April 2024 through March 2025).

Activity shows sustained procurement intensity — 20 awards in 2022 growing to 41 in 2024, with 30 awards in 2025 and nine year-to-date in 2026. Combined potential value across 383 prime awards totals $40.4 million, with $11 million obligated (27% realization rate), typical of indefinite-quantity vehicle structures where ceiling values exceed actual invoicing. The recompete cliff over the next twenty-four months carries only $59 thousand in awards completing, reflecting the rolling renewal cycle of DLA's single-award IDC vehicles rather than simultaneous cliff risk. NAICS concentration reads as Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (135 awards), Pharmaceutical Preparation Manufacturing (63 awards), and In-Vitro Diagnostic Substance Manufacturing (57 awards); PSC concentration in Medical and Surgical Instruments and In Vitro Diagnostic Substances (115 and 88 awards, respectively).

Place of performance is Japan, where Okinawa Medix operates as the established, sole-source medical supply vendor for U.S. military installations in the Pacific theater. The vendor maintains no subcontract footprint — all 383 awards are prime contracts. Seiko Co., Ltd. is identified as the parent organization, though the source provides no detail on corporate strategy, ownership structure, or synergy between parent and subsidiary beyond the UEI linkage.